Science that challenges or overturns conventional wisdom, old knowledge or what we intuitively 'know' can provide the spark that drives ongoing enquiry and the modernisation of knowledge. There are multiple examples in medicine of such challenges and the paper by Sweiss et al.
1 may add to such a list.
In this provocative paper, the stated interpretation of the data is that patients with renal impairment and myeloma who undergo autologous stem cell transplantation (autoSCT) after conditioning with melphalan 200 mg/m 2 in fact have improved disease control, despite the observed risk of increased toxicity, with a positive impact on treatment-free survival. This is, of course, the counterintuitive point of the study as it would have been predicted from previous studies in myeloma therapy that poor renal function was associated with inferior outcomes.
2,3
The recent proliferation of new therapies for myeloma with the almost infinite number of potential combinations and small studies showing progressively improving outcomes continues the recent questioning of the place of autoSCT in the myeloma treatment algorithm. Those involved in all aspects of SCT may have anticipated the demise of this form of therapy many times only to see the global activity continuing to increase, albeit with changes in focus based on new therapies. From the point of view of myeloma, two recently presented studies have confirmed the superiority of autoSCT versus its omission in the management of myeloma, and we await the confirmatory peer-reviewed publications of these studies. 4, 5 What possible explanation can there be for the observed improvement in outcomes in the study by Sweiss? It is possible that the apparent improvement in treatment-free survival observed in this study was an artefact of small sample size and the retrospective nature of the study. Given that prior exposure to the proteasome inhibitor, bortezomib correlated with improved outcome as well, it is also possible that what is being observed is one of the selection of patients destined to do well despite the initially unfavourable renal function profiles.
Previous work has suggested that exposure to high-dose alkylating agents possibly remains the most active form of disease controlling therapy in myeloma.
6-8 Studies attempting to increase the dose of melphalan generally resulted in unacceptable toxicity despite encouraging disease-control signals although some agents such as amifostine 9 may have at least partially overcome this effect. So far, these observations have not been translated into changes in standard clinical practice. Combination alkylating agent therapy offered similar outcomes. 10 It is likely that in the study by Sweiss, the patient group was such that the amount of renal impairment in the patient population resulted in just enough additional exposure to melphalan without overwhelming toxicity resulting in a balance in favour of disease control in these patients.
If these findings are generally applicable, the argument is probably that appropriate use of therapeutic drug monitoring (as is now often used to manage busulphan dosing in conditioning therapy) 11 may help to define doses of melphalan for patients undergoing autoSCT for myeloma that will optimise outcomes on an individual patient basis. This is one of the promises of 'personalised medicine'.
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